Skip to main content
SpringerLink
Log in

Hypnotika und Sedativa

  • Chapter
Arzneiverordnungs-Report 2012

  • 1361 Accesses

Zusammenfassung

Schlafstörungen gehören zu den häufigsten Gesundheitsbeschwerden in der Bevölkerung. Im Vordergrund der Beschwerden steht die subjektive Wahrnehmung des nicht erholsamen Schlafes, die sich einerseits als mangelnder nächtlicher Schlaf und andererseits als übermäßige Tagesschläfrigkeit manifestieren kann (Riemann und Hajak 2009a, Morin und Benca 2012).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Academy of Sleep Medicine (2005): The international Classification of sleep disorders. 2nd Ed.

    Google Scholar 

  • Anonym (2007): Zolpidem (Stilnox u. a.): Schlafwandeln, „Schlafessen" und „Schlaffahren". Arzneitelegramm 38: 31-32.

    Google Scholar 

  • Becker HF, Mayer G, Penzel T (2004): Schlafstörungen und schlafbezogene Atmungsstörungen. Internist 45: 57-81.

    Article  PubMed  CAS  Google Scholar 

  • Bjorvatn B, Fiske E, Pallesen S (2011) A self-help book is better than sleep hygiene advice for insomnia: a randomized controlled comparative study. Scand J Psychol. 52: 580-585.

    Article  PubMed  Google Scholar 

  • Black JE, Brooks SN, Nishino S (2004): Narcolepsy and syndromes of primary excessive daytime somnolence. Semin Neurol 24: 271-282.

    Article  PubMed  Google Scholar 

  • Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005): Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9: 41-50.

    Article  PubMed  Google Scholar 

  • Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (2005): The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20: 1151-1158.

    Article  Google Scholar 

  • Cardinali DP, Golombek DA (2009): Let there be sleep - on time. Lancet 373: 439-441.

    Article  PubMed  Google Scholar 

  • Cimolai N (2007): Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 53: 2124-2129.

    PubMed  Google Scholar 

  • Crestani F, Martin JR, Möhler H, Rudolph U (2000): Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131: 1251-1254.

    Article  PubMed  CAS  Google Scholar 

  • Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM) (2009): S3- Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 13: 4-160. Internet: www.awmf.org/leitlinien/detail/ll/063-001.html

  • Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004): Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 19: 305-322.

    Article  PubMed  Google Scholar 

  • European Medicines Agency (2007): Circadin. Europäischer öffentlicher Beurteilungsbericht (EPAR). Internet: www.emea.europa.eu/humandocs/ PDFs/EPAR/circadin/ H-695-en6.pdf

  • European Medicines Agency (2008): Fragen und Antworten zur Rücknahme des Antrags auf Genehmigung für das Inverkehrbringen von Ramelteon. EMEA/549000/2008. Internet: www.ema.europa.eu/ema/pages/includes/document/open_document.jsp webContentId=WC500064883

  • European Medicines Agency (2009/2011): Guideline on medicinal products for the treat- ment of insomnia. EMA/CHMP/16274/2009. Internet: www.ema.europa.eu/ema/ pages/includes/document/open_document.jspwebContentId=WC500102351

  • Garcia-Borreguero D, Odin P, Schwarz C (2004): Restless legs syndrome: an overview of the current understanding and management. Acta Neurol Scand 109: 303-317.

    Article  PubMed  CAS  Google Scholar 

  • Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE (2003): Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 23: 260-268.

    PubMed  CAS  Google Scholar 

  • Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005): Sedative hypnotics in older people with insomnia : meta-analysis of risks and benefits. Br Med J 331: 1169.

    Article  Google Scholar 

  • Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003): Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98: 1371-1378.

    Article  PubMed  CAS  Google Scholar 

  • Happe S (2003): Excessive daytime sleepiness and sleep disturbances in patients with neu- rological diseases: epidemiology and management. Drugs 63: 2725-2737.

    Article  PubMed  Google Scholar 

  • Haupt M, Cruz-Jentoft A, Jeste D (2006): Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol 26:566-570.

    Article  PubMed  CAS  Google Scholar 

  • Herxheimer A (2005): Jet lag. Clin Evid 13: 2178-2183.

    PubMed  Google Scholar 

  • Herxheimer A, Petrie KJ (2002): Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002; (2): CD001520

    Google Scholar 

  • Hoffmann F, Scharffetter W, Glaeske G (2009): Verbrauch von Zolpidem und Zopiclon auf Privatrezepten zwischen 1993 und 2007. Nervenarzt 80: 578-583.

    Article  PubMed  CAS  Google Scholar 

  • Hoffmann F, Pfannkuche M, Glaeske G (2008): Hochverbrauch von Zolpidem und Zopiclon Querschnittsstudie auf Basis von Krankenkassendaten. Nervenarzt 79: 67-72.

    Article  PubMed  CAS  Google Scholar 

  • Hohagen F, Rink K, Käppler C, Schramm E, Riemann D, Weyerer S, Berger M (1993): Prevalence and treatment of insomnia in general practice. European Archives of Psychiatry and Clinical Neuroscience 242: 329-336.

    Article  PubMed  CAS  Google Scholar 

  • Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW (2004): Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 164: 1888-1896.

    Article  PubMed  Google Scholar 

  • Klotz U (1995): Benzodiazepin-Hypnotika; Pharmakokinetik. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd 2. Springer-Verlag, Wien, S. 135-139.

    Google Scholar 

  • Kripke DF, Langer RD, Kline LE (2012): Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012 Feb 27;2(1):e000850.

    Google Scholar 

  • Krystal AD, Walsh JK, Laska E Caron J, Amato DA, Wessel TC, Roth T (2003): Sustained efficacy of eszopiclonover 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26:793-799.

    PubMed  Google Scholar 

  • Lader M (1987): Clinical Pharmacology of Benzodiazepines. Ann Rev Med 38: 19-28.

    Article  PubMed  CAS  Google Scholar 

  • Lader MH (2001): Implications of hypnotic flexibility on patterns of clinical use. Int J Clin Pract 116 (Suppl): 14-19.

    Google Scholar 

  • Lancee J, van den Bout J, van Straten A, Spoormaker VI (2012) Interne t-delivered or mailed self-help treatment for insomnia?: a randomized waiting-list controlled trial. Behav Res Ther. 50: 22-29.

    Article  PubMed  Google Scholar 

  • Lemoine P, Nir T, Laudon M, Zisapel N (2007): Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16: 372-380.

    Article  PubMed  Google Scholar 

  • Mattila T, Stoyanova V, Elferink A, Gispen-de Wied C, de Boer A, Wohlfarth T (2011): Insomnia medication: do published studies reflect the complete picture of efficacy and safety? Eur Neuropsychopharmacol 21: 500-507.

    Article  PubMed  CAS  Google Scholar 

  • Ministry of Health and Social Policy (2009): Clinical practice guidelines for the management of patients with insomnia in primary care. Madrid. Internet: www.guiasalud.es/ egpc/traduccion/ingles/insomnio/completa/

  • Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M (2003): Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic ran- domised controlled trial. Br J Gen Pract 53: 923-928.

    PubMed  Google Scholar 

  • Morin CM, Benca R (2012): Chronic insomnia. Lancet 379: 1129-1141.

    Article  PubMed  Google Scholar 

  • Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL (2006): Psychological and behavioral treatment of insomnia. Sleep 29: 1398-1414.

    PubMed  Google Scholar 

  • National Institute for Clinical Excellence, Technology appraisal guidance 77 (2004): Zaleplon, Zolpidem and zopiclone for the short term management of insomnia. Internet: www.nice.org.uk/TA077.

  • National Institutes of Health state of the science conference statement (2005): Manifestations and management of chronic insomnia in adults. Sleep 28: 1049-1057.

    Google Scholar 

  • Ohayon MM (2002): Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6: 97-111.

    Article  PubMed  Google Scholar 

  • Perlis ML, McCall WV, Krystal AD, Walsh JK (2004): Long-term, non-nightly administration of Zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65: 1128-1137.

    Article  PubMed  CAS  Google Scholar 

  • Riemann D, Hajak G (2009a): Insomnien. I. Ätiologie, Pathophysiologie und Diagnostik. Nervenarzt 80: 1060-1069.

    Article  Google Scholar 

  • Riemann D, Hajak G (2009b): Insomnien. II. Pharmakologische und psychotherapeutische Behandlungsmöglichkeiten. Nervenarzt 80: 1327-1340.

    Article  Google Scholar 

  • Sack RL (2010): Clinical practice. Jet lag.N Engl J Med 362: 440-447.

    Article  CAS  Google Scholar 

  • Sarris J, Byrne GJ (2011): A systematic review of insomnia and complementary medicine. Sleep Med Rev 15: 99-106.

    Article  PubMed  Google Scholar 

  • Sateia MJ, Nowell PD (2004): Insomnia. Lancet. 364: 1959-73.

    Article  PubMed  Google Scholar 

  • Schenck CH, Mahowald MW, Sack RL (2003): Assessment and management of insomnia. JAMA 289(19): 2475-2479.

    Article  PubMed  Google Scholar 

  • Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149-158.

    Article  PubMed  CAS  Google Scholar 

  • Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M (2008): Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 4: 487-504.

    PubMed  Google Scholar 

  • Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X et al (2006): Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 51: 27-34.

    PubMed  Google Scholar 

  • Simen S, Hajak G, Schlaf G, Westenhöfer J, Rodenbeck A, Bandel B, Pudel V, Rüther E (1995): Chronifizierung von Schlafbeschwerden. Nervenarzt 66: 686-695.

    PubMed  CAS  Google Scholar 

  • Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L (2003): New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 26: 261-282.

    Article  PubMed  CAS  Google Scholar 

  • Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK, Ware JC (2000): Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23:1087-1096.

    PubMed  CAS  Google Scholar 

  • Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T (2007): Nightly treatment of primary insomnia with eszopi- clone for six months: effect on sleep, quality of life, and work limitations. Sleep. 30: 959-968.

    PubMed  Google Scholar 

  • Weyerer S, Dilling H (1991): Prevalence and treatment of insomnia in the Community: Results from the upper Bavarian field study. Sleep 14: 392-398.

    PubMed  CAS  Google Scholar 

  • Wiegand MH (2003): Arzneimittelbehandlung von Schlafstörungen im Alter. Internist 44: 1187-1192.

    Article  PubMed  CAS  Google Scholar 

  • Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG (2010): British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and cir- cadian rhythm disorders. J Psychopharmacol 24: 1577-1601.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Straße 9, 97078, Würzburg

    Prof. Dr. med. Martin J. Lohse

  2. Bartningallee 11–13, 10555, Berlin

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Medizin Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Lohse, M., Müller-Oerlinghausen, B. (2012). Hypnotika und Sedativa. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-29242-2_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-29241-5

  • Online ISBN: 978-3-642-29242-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation